Peanut AllergyNCT02821286
Identification of Anaphylactogenic Antibodies in Peanut Allergy
An observational study of Peanut Allergy, run by University of Zurich.
Trial summary
This project intends the analysis and profiling of specific antibodies against major peanut allergens in peanut allergic individuals and molecular cloning of human antibodies against major peanut allergens. Read more about this study
- Who is it for?
- Ages 3 years and older
- Conditions the study is for
- Peanut Allergy
- What is being tested?
- Observational study
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- Jun 2016to Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The project population includes patients of at least three years of age with a described history of peanut allergy and/or sensitization to peanut allergens (as evidenced by positive skin prick test or allergen-specific IgE testing).
Who may be able to join
- Participants have a described clinical history of peanut allergy and/or are sensitized to peanut allergens (as evidenced by positive skin prick test and allergen-specific IgE testing)
- Male and female subjects older than 3 years
- Written informed consent
Who cannot join
- age below three years
- patients suffering from any disease where blood withdrawals might impact the patients' health status such as known anemia.
About this study
Official title: Identification of Anaphylactogenic Antibodies in the Blood of Peanut Allergic Patients
This project intends the analysis and profiling of specific antibodies against major peanut allergens in peanut allergic individuals and molecular cloning of human antibodies against major peanut allergens.
Read the detailed description
- Characterization of patient samples reactivity (sera obtained from blood) against major peanut allergens.
- Isolation of antibody-producing B cells.
- Molecular cloning of peanut-specific antibodies from antibody gene sequences obtained from B cells.
- Biophysical and functional characterization of isolated antibodies
- Conditions
- Peanut Allergy
- Being tested
- Observational study
- Medical subject headings
- Peanut Hypersensitivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Observational studyOther
Blood sampling
What is being measured
The primary outcome is the main question the study is designed to answer.
Analysis and profiling of specific antibodies against major peanut allergens in samples derived from peanut allergic patients.
Measured: June 2016 to May 2018
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2016 (estimated)
- Study startJun 2016
- Primary completionDec 2025 (estimated)
- Study completionDec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Peanut AllergyStudies of the same condition, open and under way.
- More trials run by University of ZurichThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Zurich
- Sponsor type
- University, hospital or other
- Collaborators
- University Children's Hospital, Zurich
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02821286
- Sponsor's protocol ID
- UZH
- Status last verified
- Dec 2023
- First submitted
- 29 Jun 2016
- Last updated
- 20 Dec 2023
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Identification of Anaphylactogenic Antibodies in the Blood of Peanut Allergic Patients
- ClinicalTrials.gov ID
- NCT02821286
- Acronym / sponsor ID
- UZH
- Conditions
- Peanut Allergy
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University of ZurichUniversity, hospital or other
- Collaborators
- University Children's Hospital, Zurich
- Study start
- Jun 2016
- Primary completion
- Dec 2025 (estimated)
- Study completion
- Dec 2025 (estimated)
- First posted
- 1 Jul 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This project intends the analysis and profiling of specific antibodies against major peanut allergens in peanut allergic individuals and molecular cloning of human antibodies against major peanut allergens.
Detailed description
- Characterization of patient samples reactivity (sera obtained from blood) against major peanut allergens.
- Isolation of antibody-producing B cells.
- Molecular cloning of peanut-specific antibodies from antibody gene sequences obtained from B cells.
- Biophysical and functional characterization of isolated antibodies
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 3 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The project population includes patients of at least three years of age with a described history of peanut allergy and/or sensitization to peanut allergens (as evidenced by positive skin prick test or allergen-specific IgE testing).
Key inclusion criteria (3 listed)
- Participants have a described clinical history of peanut allergy and/or are sensitized to peanut allergens (as evidenced by positive skin prick test and allergen-specific IgE testing)
- Male and female subjects older than 3 years
- Written informed consent
Key exclusion criteria (2 listed)
- age below three years
- patients suffering from any disease where blood withdrawals might impact the patients' health status such as known anemia.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Observational studyBlood sampling | Other | – |
Primary outcome
Analysis and profiling of specific antibodies against major peanut allergens in samples derived from peanut allergic patients.
Time frame: June 2016 to May 2018
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Dec 2023.
- Individual participant dataSharing planned: No
Related trials for Peanut Allergy
Active, not recruitingPhase 2
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
Immune System Diseases, Ig-E Mediated Food Allergy
Active, not recruitingPhase 2
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
Peanut Allergy, Peanut Hypersensitivity
Not yet recruiting
Oral Immunotherapy for Children With Peanut Allergy
Peanut Allergic Subjects, Peanut Allergies
RecruitingObservational study
Study of Oral Food Challenge Biomarkers (SAFER)
Allergy
Active, not recruitingObservational study
EPAP, Interviewstudy
Food Allergy, Food Allergy Peanut
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Peanut Allergy, run by University of Zurich.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Analysis and profiling of specific antibodies against major peanut allergens in samples derived from peanut allergic patients. (time frame: June 2016 to May 2018). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2023.